U.S. markets closed
  • S&P 500

    3,841.94
    +73.47 (+1.95%)
     
  • Dow 30

    31,496.30
    +572.16 (+1.85%)
     
  • Nasdaq

    12,920.15
    +196.68 (+1.55%)
     
  • Russell 2000

    2,192.21
    +45.29 (+2.11%)
     
  • Crude Oil

    66.28
    +2.45 (+3.84%)
     
  • Gold

    1,698.20
    -2.50 (-0.15%)
     
  • Silver

    25.30
    -0.17 (-0.65%)
     
  • EUR/USD

    1.1925
    -0.0054 (-0.45%)
     
  • 10-Yr Bond

    1.5540
    +0.0040 (+0.26%)
     
  • GBP/USD

    1.3827
    -0.0067 (-0.48%)
     
  • USD/JPY

    108.2450
    +0.2690 (+0.25%)
     
  • BTC-USD

    48,741.12
    +1,775.07 (+3.78%)
     
  • CMC Crypto 200

    982.93
    +39.75 (+4.21%)
     
  • FTSE 100

    6,630.52
    -20.36 (-0.31%)
     
  • Nikkei 225

    28,864.32
    -65.78 (-0.23%)
     

The Week Ahead In Biotech: FDA Decision On G1 Therapeutics, Earnings In The Mix For Light Calendar Week

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Shanthi Rexaline
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Biotech stocks advanced in the week ended Feb. 12, thanks to broader market strength and company-specific catalysts. Small and mid-cap earnings, multiple conference presentations, data readouts and a slew of IPOs were all part of the week's news flow.

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) received two FDA approvals during the week. Immunotherapy Libtayo, which the company co-developed with Sanofi SA (NASDAQ: SNY), got a label expansion as a treatment option for basal cell carcinoma. Regeneron also received the nod for its Evkeeza, as an adjunctive treatment option for ultra-rare cholesterol disease.

Ocugen Inc (NASDAQ: OCGN) and Kalvista Pharmaceuticals Inc (NASDAQ: KALV) were among the best performing stocks of the week. The former moved on momentum gathered on the back of a U.S. COVID-19 vaccine deal with Bharat Biotech and the news of an offering priced at a premium. Kalvista gained on a positive data readout.

Conferences

BIO CEO & Investor Digital Conference: Feb. 16-18

PDUFA Dates

The FDA is set to rule on G1 Therapeutics Inc's (NASDAQ: GTHX) new drug application for trilaciclib as a treatment option for mitigating the impact of chemotherapy in small-cell lung cancer. The PDUFA date by which the verdict has to be issued is Monday, Feb. 15.

Related Link: Pharma Stock Ideas: Why BMO Is Recommending Regeneron, Constellation

Earnings

Monday

Medpace Holdings Inc (NASDAQ: MEDP)

Tuesday

View more earnings on IBB

Zoetis Inc (NYSE: ZTS) (before the market open)
EXACT Sciences Corporation (NASDAQ: EXAS) (after the market close)

Wednesday

Royalty Pharma plc (NASDAQ: RPRX) (before the market open)
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) (before the market open)
Blueprint Medicines Corp (NASDAQ: BPMC) (before the market open)
10X Genomics Inc (NASDAQ: TXG) (after the close)
Invitae Corp (NYSE: NVTA) (after the close)
Globus Medical Inc (NYSE: GMED) (after the close)
Shockwave Medical Inc (NASDAQ: SWAV) (after the close)
Veracyte Inc (NASDAQ: VCYT) (after the close)
Viking Therapeutics Inc (NASDAQ: VKTX) (after the close)

Thursday

West Pharmaceutical Services Inc. (NYSE: WST) (before the market open)
Syneos Health Inc (NASDAQ: SYNH) (before the market open)
Avanos Medical Inc (NYSE: AVNS) (before the market open)
Integra Lifesciences Holdings Corp (NASDAQ: IART) (before the market open)
Emergent Biosolutions Inc (NYSE: EBS) (after the close)
Quidel Corporation (NASDAQ: QDEL) (after the close)
Opko Health Inc. (NASDAQ: OPK) (after the close)

Related Link: Novavax Shares Pass The 0 Mark: Is The Rally Sustainable?

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.